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Abstract
Background Although younger patients are supposed to be
less susceptible to bleeding complications of mechanical aor-
tic valve replacement (mAVR) than older patients, there is a
relative paucity of data on this subject. Therefore, it remains
uncertain whether younger patients are really at a lower risk of
these complications than older patients.
Methods Incidence rates of bleeding events during 15 years of
follow-up after mAVR were compared between 163 patients
under 60 (group I), 122 patients between 60 and 65 (group II),
and 145 patients over 65 (group III) years of age at operation.
The target international normalised ratio (INR) was 3.0–4.0.
Results During 15 years of follow-up, the annual incidence
rate of major bleeding events (excluding haemorrhagic stroke)
was lower in the youngest as compared with the oldest group
(3.0 versus 4.7 %, respectively; p=0.030). However, the an-
nual incidence rate of haemorrhagic stroke was as high in the
youngest as in the two older groups (0.6 versus 0.7 % and
0.7 %, respectively; p=0.928).
Conclusions With a target INR of 3.0–4.0, patients under
60 years of age are at equally high risk of haemorrhagic stroke
after mAVR as older patients. This finding confirms the rele-
vance of a lower target INR as used in international
guidelines.
Keywords Aortic valve . Heart valve prosthesis . Intracranial
haemorrhage . Coumarin
Introduction
Mechanical aortic valve replacement (mAVR) is generally
reserved for patients under the age of 60 years because of
the durability of a mechanical prosthesis and a supposed lower
susceptibility of younger patients to bleeding complications of
oral anticoagulation therapy [1–5]. However, there is a relative
paucity of data on long-term bleeding events after mAVR in
patients under 60 years [6–8]. Therefore, it remains uncertain
whether younger patients are really at lower risk of these
complications than older patients. We aimed to compare inci-
dence rates of bleeding events between patients under 60 and




In this retrospective longitudinal cohort study, 430 patients
were followed for 15 years after mAVR, which was performed
in the St. Antonius Hospital in Nieuwegein, the Netherlands,
between 1990 and 1994. Incidence rates of bleeding events,
occurring after discharge from hospital, were compared be-
tween three groups of patients: 163 patients under 60 (group
I), 122 patients between 60 and 65 (group II), and 145 patients
over 65 (group III) years of age at operation. Target interna-
tional normalised ratio (INR) of oral anticoagulation therapy
was 3.0–4.0, which was the standard at that time regarding
mechanical aortic prostheses [9]. During follow-up, target
INR did not change [10]. Data were obtained from our own
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or the referring cardiology departments, general practitioners,
and telephone calls to patients and relatives. INR values
within 48 h of the bleeding events, except the minor ones,
were retrieved from the regional thrombosis services. The
study object was agreed upon by the Hospital Committee on
Ethics and Medical Experiments.
Definitions
Bleeding events were divided into minor and major bleeding
and haemorrhagic stroke events. Definitions were based on
the official guidelines for reporting mortality and morbidity
after cardiac valve interventions [11] and defined as follows.
Minor bleeding: bleeding not requiring admission or blood
transfusion. Major bleeding: fatal or nonfatal bleeding requir-
ing admission or blood transfusion, excluding haemorrhagic
stroke. Haemorrhagic stroke: focal neurological deficit of
sudden onset as diagnosed by a neurologist, lasting more than
24 h and caused by cerebral bleeding.
Data analysis
Calculation of late overall mortality was performed by
Kaplan-Meier analysis. To calculate incidence rates of first
bleeding events, Kaplan-Meier cumulative incidence rates
were computed, whereas formal hypothesis testing was done
by means of the log-rank test. To calculate incidence rates of
multiple events (up to three per patient for minor or major
bleeding events, and up to two for haemorrhagic stroke),
linearised annual incidence rates (% per year, with exact
95 % confidence intervals [CI]) were computed, whereas




Baseline characteristics are depicted in Table 1. The youngest
patient was 21 and the oldest 80 years of age at operation. In
all three groups more male than female patients were operated
upon. In patients under 60 years at operation, mAVR was
more often performed because of aortic regurgitation, as com-
pared with aortic stenosis in the older groups. None of the
patients had a history of haemorrhagic stroke.
Mechanical protheses
The different types of implanted mechanical aortic valve
prostheses are depicted in Table 2. They were similarly dis-
tributed among the three groups, half of them being bileaflet
and the other half tilting disc prostheses.
Follow-up
Mean follow-up after mAVRwas 18.1±1.2 years. All patients
were followed for at least 15 years after operation or until
death. Follow-up was complete in all patients.
Table 1 Baseline characteristics
Values are presented as mean±
standard deviation or N (%)
CABG coronary artery bypass
grafting
*Serum creatinine >2.3 mg/dl










Age (years) 50.4±7.9 62.7±1.8 68.7±2.7
Male 117 (71.8) 77 (63.1) 95 (65.5)
EuroSCORE II 1.2±1.1 1.9±1.9 2.6±3.0
Logistic EuroSCORE 2.5±2.2 3.6±4.2 5.6±7.1
STS score (version 2.73) 1.0±0.9 1.5±1.2 2.0±1.7
Concomitant CABG 26 (16.0) 32 (26.2) 48 (33.1)
Predominant aortic stenosis 108 (66.3) 104 (85.2) 120 (82.8)
Body mass index (kg/m2) 26±3 26±4 25±3
Insulin dependent diabetes 0 1 (0.8) 5 (3.4)
Non-insulin dependent diabetes 5 (3.1) 7 (5.7) 18 (12.4)
Paroxysmal atrial fibrillation 9 (5.5) 9 (7.4) 17 (11.7)
Permanent atrial fibrillation 4 (2.5) 2 (1.6) 14 (9.7)
Renal failure* 3 (1.8) 0 2 (1.4)
Hypertension 76 (46.6) 58 (47.5) 75 (51.7)
History of ischaemic stroke 6 (3.7) 1 (0.8) 13 (9.0)
History of gastrointestinal bleeding 0 5 (4.1) 7 (4.8)
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Thirty-day and late mortality
Thirty-day mortality rates were 1.2, 1.6, and 2.8 % in group I,
II, and III, respectively. Kaplan-Meier late overall cumulative
mortality rates (including the patients who died within 30 days
of operation) at 15 years of follow-up were 27.6 % (95 % CI:
20.4–34.2), 53.6 % (95 % CI: 43.8–61.7), and 73.1 % (95 %
CI: 64.8–79.4) in group I, II, and III, respectively.
Bleeding events
Incidence rates of bleeding events are depicted in Table 3.
Total numbers of patient-years of follow-up were 2479, 1541,
and 1481 years in group I, II, and III, respectively. During
15 years of follow-up, the annual incidence rate of major
bleeding events (excluding haemorrhagic stroke) was lower
in the youngest as compared with the oldest group (3.0 versus
4.7 %, respectively; p=0.030). However, the annual incidence
rate of haemorrhagic stroke was as high in the youngest as in
the two older groups (0.6 versus 0.7 % and 0.7 %,
respectively; p=0.928). Incidence rates of bleeding events
did not change over the 15 years of follow-up.
Related INR values
During 15 years of follow-up, a total of 206 first or recurrent
major bleeding events (excluding haemorrhagic stroke) and
36 first or recurrent haemorrhagic stroke events occurred. The
mean INR within 48 h of these 242 events was 4.0±1.5
(range: 1.5–9.4). In 74 (30.6 %) of these 242 events, the
INR value was not available.
Related INR values in patients under 60 years at operation
In the 163 patients under 60 years of age at operation (group
I), 48 patients suffered a first major bleeding event (excluding
haemorrhagic stroke). The related mean INR was 4.1±1.2
(range: 2.3–7.5), whereas the INR was unavailable in 15
(31.3 %) of these patients. In the 48 patients with a first major
bleeding event (excluding haemorrhagic stroke), one event
was fatal (related INR: 4.2). In group I, 14 patients suffered
a first haemorrhagic stroke. The related mean INR was 3.4±
0.8 (range: 2.2–4.8), whereas the INR was unavailable in 3
(21.4 %) of these patients. In the 14 patients with a first
haemorrhagic stroke, 8 events were fatal. The related mean
INR was 3.8±0.7 (range: 3.0–4.8), whereas the INR was
unavailable in 2 (25.0 %) of these patients.
In group I, 15 patients were younger than 40 years at
operation. Three of them, all males, suffered a first major
bleeding event (excluding haemorrhagic stroke) at age 34,
29, and 46 years (5.8, 0.8, and 8.2 years after mAVR, respec-
tively). None of these events were fatal and the related INR
values were 3.2, 3.8, and 4.1, respectively. One of these 15
patients suffered a haemorrhagic stroke at age 44 (10 years
after mAVR). This event was fatal (related INR: 3.4).











St. Jude Medical 79 (48.5) 58 (47.5) 68 (46.9)
St. Jude Medical
Hemodynamic Plus
1 (0.6) 1 (0.8) 1 (0.7)
Sorin Bicarbon 3 (1.8) 4 (3.3) 4 (2.8)
Tilting disc prostheses
Sorin Allcarbon 80 (49.1) 59 (48.4) 72 (49.7)
Values are presented as N (%)












Kaplan-Meier cumulative incidence of first events (%; 95 % CI) 45.7 (36.9–53.3) 47.9 (36.6–57.1) 51.3 (38.8–61.3) P=0.783
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) 5.5 (4.6–6.5) 6.2 (5.1–7.6) 7.0 (5.7–8.4) P=0.278
Major bleeding (excluding haemorrhagic stroke)
Kaplan-Meier cumulative incidence of first events (%; 95 % CI) 29.9 (21.9–37.1) 34.2 (23.7–43.3) 42.7 (31.2–52.3) P=0.052
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) 3.0 (2.4–3.7) 4.0 (3.1–5.1) 4.7 (3.7–5.9) P=0.030*
Haemorrhagic stroke
Kaplan-Meier cumulative incidence of first events (%; 95 % CI) 7.6 (3.2–11.9) 9.6 (3.3–15.6) 7.5 (2.6–12.1) P=0.947
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) 0.6 (0.3–1.0) 0.7 (0.4–1.3) 0.7 (0.3–1.2) P=0.928
CI confidence interval
*Group I vs. III
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Discussion
In this study, incidence rates of bleeding events during 15 years
of follow-up after mAVR were determined in a group of
patients under 60 years of age, and compared with two groups
of patients aged between 60 and 65 and over 65 years at
operation, respectively. The patients under 60 years of age
were not at low risk of long-term bleeding complications as
compared with the older patients. Although the annual inci-
dence rate of major bleeding events (excluding haemorrhagic
stroke) was lower in the youngest as compared with the oldest
group (3.0 versus 4.7 %, respectively; p=0.030), the annual
incidence rate of haemorrhagic stroke was as high in the
youngest as in the two older groups (0.6 versus 0.7 % and
0.7 %, respectively; p=0.928). We do not know why the
patients under 60 years, despite their younger age, were at
equally high risk of haemorrhagic stroke as the older patients.
There were no suggestions of a selection of younger patients
more prone to bleeding, because risk factors for bleeding
(female gender, renal failure, hypertension, history of ischae-
mic stroke or gastrointestinal bleeding) were not more com-
mon in the youngest than in the older groups (Table 1). Our
finding that younger patients on oral anticoagulation therapy
were not at lower risk of haemorrhagic stroke than older
patients is confirmed by a study in 42 both younger and older
patients (24 % of patients under 65, 59 % of patients between
65 and 79, and 17 % of patients over 79 years of age) who
suffered a haemorrhagic stroke while they were on oral
anticoagulation therapy because of atrial fibrillation (57 % of
patients), venous thromboembolism (24 % of patients), and/or
prosthetic heart valves (14 % of patients) [12]. The mean INR
on admission in this study was 3.6±2.1 for the whole patient
group (INR values in the patients under the age of 65 were not
available), which is comparable with the mean INR of 3.4±
0.8 within 48 h of the haemorrhagic stroke events in the
youngest age group of the present study. The target INR of
3.0–4.0 in our patients did not change during the 15 years of
follow-up. From the literature it is known that annual inci-
dence rates of major bleeding and haemorrhagic stroke events
in patients on oral anticoagulation therapy with a target INR of
3.0–4.0 are approximately 3.0 and 0.6 %, respectively (com-
parable with the present study), while annual incidence rates
of major bleeding and haemorrhagic stroke events with a
lower target INR of 2.0–3.0 are reported to be approximately
2.0 and 0.5 %, respectively [13–17]. Excessive INR values
(above 5.0) are associated with very high bleeding rates [18,
19]. Current [20, 21] and past [22] international guidelines
recommend a target INR of 2.0–3.0 to 2.5–3.5 (depending on
prosthesis thrombogenicity and patient-related risk factors for
thromboembolism) for most mechanical aortic valves of the
last decades, including the prostheses used in the present
study. These target INR values are based on studies, including
three major randomised trials [23–25], weighing
thromboembolic risks against haemorrhagic risks in patients
on oral anticoagulation therapy after mechanical heart valve
replacement. Although we do not know what the bleeding
figures in our patients would have been if the target INR had
been as low as in the international guidelines, it seems plau-
sible that with a lower target INR the incidence rates of both
major bleeding and haemorrhagic stroke events would have
been lower in all three age groups. An important shortcoming
of the present study is the high percentage (30.6 %) of un-
available INR values within 48 h of the major bleeding and
haemorrhagic stroke events. It is therefore not known how
many patients might have suffered these events due to an
excessively high INR. However, the INR values which were
available within 48 h of the major bleeding or haemorrhagic
stroke events were not excessively high.
Conclusions
With a target INR of 3.0–4.0, patients under 60 years of age
are at equally high risk of haemorrhagic stroke after mAVR as
older patients. This finding confirms the relevance of a lower
target INR as used in international guidelines.
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